HI-Bio's felzartamab shows 82% rejection resolution in late antibody-mediated rejection in kidney transplant recipients, outperforming placebo.
HI-Bio reports positive Phase 2 results for felzartamab in treating late antibody-mediated rejection in kidney transplant recipients. In the study, 82% of patients on felzartamab experienced rejection resolution versus 20% on placebo. Treated patients showed reduced disease-linked biomarkers and eGFR stabilization. The results support felzartamab's advancement into late-stage development as a novel therapeutic for antibody-mediated rejection.
May 25, 2024
3 Articles